Compare Kyndryl Holdings Inc (KD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs TransMedics Group Inc — how do they compare? Kyndryl Holdings Inc trades at $11.69 (market cap $2.59B), while TransMedics Group Inc trades at $78.42 (market cap $2.74B). The key difference: Kyndryl Holdings Inc and TransMedics Group Inc are close in size by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and TransMedics Group Inc for 24 Days on average.
| KD | TMDX | |
|---|---|---|
Market Cap | $2.59B | $2.74B |
Volume | 5,354,348 | 949,331 |
Sector | Technology | Health |
52-Week High | $29.76 | $150.42 |
52-Week Low | $10.59 | $61.99 |
Typical Hold Time | 36 Days | 24 Days |
Enterprise Value | $5.41B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.67, up 1.92% today, with a bearish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights a strategic focus on AI, including a new innovation lab and acquisitions, aiming to drive future growth amid competitive pressures.
The outlook is mixed: positive cash flow and low EV/EBITDA suggest value, but declining revenue and modest analyst consensus ($14.67 target) indicate caution. Key risks include execution on AI initiatives and sustained top-line pressure. Institutional sentiment is neutral with 71% hold ratings, reflecting a wait-and-see approach amid transformation efforts.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
